Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques

This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of virology Ročník 89; číslo 13; s. 6773
Hlavní autori:	Alfson, Kendra J, Avena, Laura E, Beadles, Michael W, Staples, Hilary, Nunneley, Jerritt W, Ticer, Anysha, Dick, Jr, Edward J, Owston, Michael A, Reed, Christopher, Patterson, Jean L, Carrion, Jr, Ricardo, Griffiths, Anthony
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.07.2015
Predmet:	Animals Disease Models, Animal Ebolavirus - growth & development Ebolavirus - pathogenicity Ebolavirus - physiology Haplorhini Hemorrhagic Fever, Ebola - mortality Hemorrhagic Fever, Ebola - pathology Hemorrhagic Fever, Ebola - virology Macaca fascicularis Serial Passage Survival Analysis Viral Load Viral Plaque Assay Virulence
ISSN:	1098-5514, 1098-5514
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque (Macaca fascicularis) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo. These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures. Ebola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo. Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.
AbstractList	This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque (Macaca fascicularis) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo. These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures. Ebola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo. Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures. This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque (Macaca fascicularis) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo. These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.UNLABELLEDThis study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque (Macaca fascicularis) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo. These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.Ebola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo. Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.IMPORTANCEEbola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo. Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.
Author	Patterson, Jean L Alfson, Kendra J Ticer, Anysha Griffiths, Anthony Beadles, Michael W Carrion, Jr, Ricardo Dick, Jr, Edward J Reed, Christopher Nunneley, Jerritt W Staples, Hilary Avena, Laura E Owston, Michael A
Author_xml	– sequence: 1 givenname: Kendra J surname: Alfson fullname: Alfson, Kendra J – sequence: 2 givenname: Laura E surname: Avena fullname: Avena, Laura E – sequence: 3 givenname: Michael W surname: Beadles fullname: Beadles, Michael W – sequence: 4 givenname: Hilary surname: Staples fullname: Staples, Hilary – sequence: 5 givenname: Jerritt W surname: Nunneley fullname: Nunneley, Jerritt W – sequence: 6 givenname: Anysha surname: Ticer fullname: Ticer, Anysha – sequence: 7 givenname: Edward J surname: Dick, Jr fullname: Dick, Jr, Edward J – sequence: 8 givenname: Michael A surname: Owston fullname: Owston, Michael A – sequence: 9 givenname: Christopher surname: Reed fullname: Reed, Christopher – sequence: 10 givenname: Jean L surname: Patterson fullname: Patterson, Jean L – sequence: 11 givenname: Ricardo surname: Carrion, Jr fullname: Carrion, Jr, Ricardo – sequence: 12 givenname: Anthony surname: Griffiths fullname: Griffiths, Anthony
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25903348$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM9LwzAcxYNM3A-9eZYcvXQmadomRxmbCgN3cOeRpN9KRtrMpCnsv7fiBE_vHT7vPXhzNOl8BwjdU7KklImn42CXhJRcZrS4QjNKpMiKgvLJPz9F8xiPhFDOS36DpqyQJM-5mCG9U6G3xkHW-2y32eOgeuuxb_Bae6fwYEOK2HaNS9AZiLi2EVQEbHwKo6iuxjGFwQ7KjRg258633n2OoVYZ9ZUg3qLrRrkIdxddoP1m_bF6zbbvL2-r521muMj7rAYBiijalLKoamIo17JiUoNgUpGc61KLkoJWjEngTcFkM4KVrgwTuZENW6DH395T8D-7_aG10YBzqgOf4oFWhOacS8ZH9OGCJt1CfTgF26pwPvz9wr4B-u9m_w
CitedBy_id	crossref_primary_10_1111_jam_12973 crossref_primary_10_1016_j_tibtech_2020_04_010 crossref_primary_10_3390_v10110642 crossref_primary_10_1016_j_jviromet_2017_06_014 crossref_primary_10_1128_JVI_00530_19 crossref_primary_10_1002_JLB_4RI0518_183R crossref_primary_10_1093_infdis_jiw254 crossref_primary_10_3390_v9110319 crossref_primary_10_1038_s41572_020_0147_3 crossref_primary_10_1371_journal_pone_0192312 crossref_primary_10_1099_jgv_0_001481 crossref_primary_10_1128_JVI_00968_18 crossref_primary_10_1038_s41598_023_31027_7 crossref_primary_10_12688_f1000research_17573_1 crossref_primary_10_1002_JLB_4HI0420_285RR crossref_primary_10_1111_tbed_12580 crossref_primary_10_1186_s12985_021_01566_4 crossref_primary_10_3390_v10030126 crossref_primary_10_1371_journal_ppat_1007390 crossref_primary_10_3390_vaccines10081314 crossref_primary_10_1371_journal_ppat_1008282 crossref_primary_10_3390_v8040113 crossref_primary_10_3390_vaccines10111935 crossref_primary_10_1038_s41598_024_75038_4 crossref_primary_10_1371_journal_pntd_0006078 crossref_primary_10_3390_v7122969 crossref_primary_10_1016_j_coviro_2016_11_013 crossref_primary_10_1128_JVI_01098_18 crossref_primary_10_1128_mSphere_00401_17 crossref_primary_10_1038_s41541_020_00261_9 crossref_primary_10_1093_infdis_jiw267 crossref_primary_10_3390_vaccines9091045 crossref_primary_10_1016_j_jviromet_2021_114116 crossref_primary_10_3390_vaccines10060963 crossref_primary_10_1128_JVI_00179_17 crossref_primary_10_1128_JVI_00404_18 crossref_primary_10_1128_JVI_02170_19 crossref_primary_10_3390_microorganisms9030489 crossref_primary_10_1016_j_immuni_2021_01_015 crossref_primary_10_1016_j_vaccine_2025_127509 crossref_primary_10_18231_j_jpbs_2023_002
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/jvi.00649-15
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	1098-5514
ExternalDocumentID	25903348
Genre	Research Support, U.S. Gov't, Non-P.H.S Journal Article
GrantInformation_xml	– fundername: NCRR NIH HHS grantid: C06 RR012087 – fundername: NIH HHS grantid: P51 OD011133
GroupedDBID	--- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAFWJ AAGFI AAYJJ ABPPZ ACGFO ACNCT ADBBV ADXHL AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8
ID	FETCH-LOGICAL-c483t-de8ea0a1f6957d0c14b9729be829a034b6b861eba229e4f529f9577b7c283c9f2
IEDL.DBID	7X8
ISICitedReferencesCount	51
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000355593000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-5514
IngestDate	Thu Sep 04 18:01:55 EDT 2025 Mon Jul 21 06:01:32 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	13
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c483t-de8ea0a1f6957d0c14b9729be829a034b6b861eba229e4f529f9577b7c283c9f2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://jvi.asm.org/content/jvi/89/13/6773.full.pdf
PMID	25903348
PQID	1701344924
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1701344924 pubmed_primary_25903348
PublicationCentury	2000
PublicationDate	2015-07-01
PublicationDateYYYYMMDD	2015-07-01
PublicationDate_xml	– month: 07 year: 2015 text: 2015-07-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of virology
PublicationTitleAlternate	J Virol
PublicationYear	2015
References	20448082 - Toxicol Pathol. 2010 Jun;38(4):642-57 6310859 - Virology. 1983 Jul 30;128(2):310-8 21987747 - J Infect Dis. 2011 Nov;204 Suppl 3:S757-60 14633608 - Am J Pathol. 2003 Dec;163(6):2347-70 19369328 - J Virol. 2009 Jul;83(13):6917-21 7817880 - Adv Virus Res. 1994;44:69-160 24046765 - Front Microbiol. 2013 Sep 05;4:267 21987755 - J Infect Dis. 2011 Nov;204 Suppl 3:S804-9 8666162 - FASEB J. 1996 Jun;10(8):859-64 8969248 - Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 10489346 - Virology. 1999 Sep 15;262(1):114-28 19369954 - Nat Rev Microbiol. 2009 May;7(5):393-400 24011860 - Trends Microbiol. 2013 Nov;21(11):583-93 21349180 - Virol J. 2011;8:81 9988191 - J Infect Dis. 1999 Feb;179 Suppl 1:S248-58 20049699 - EMBO Mol Med. 2009 Apr;1(1):10-8 19023410 - PLoS Pathog. 2008 Nov;4(11):e1000212 12049094 - Fed Regist. 2002 May 31;67(105):37988-98 20920247 - Virol J. 2010;7:257 17921984 - Nat Biotechnol. 2007 Oct;25(10):1084-7 102747 - J Pathol. 1978 Jul;125(3):131-8 23209706 - PLoS One. 2012;7(11):e50316 22247782 - PLoS One. 2012;7(1):e29608 16588529 - Proc Natl Acad Sci U S A. 1942 Apr;28(4):127-130.1 13456358 - Virology. 1957 Aug;4(1):41-52 21047966 - J Virol. 2011 Jan;85(2):1025-35 23223188 - Viruses. 2012 Dec;4(12):3511-30 7041255 - Science. 1982 Mar 26;215(4540):1577-85 25244186 - N Engl J Med. 2014 Oct 16;371(16):1481-95 11602743 - J Virol. 2001 Nov;75(22):11025-33 24738640 - N Engl J Med. 2014 Oct 9;371(15):1418-25 20439981 - Am J Trop Med Hyg. 2010 May;82(5):954-60
References_xml	– reference: 102747 - J Pathol. 1978 Jul;125(3):131-8 – reference: 12049094 - Fed Regist. 2002 May 31;67(105):37988-98 – reference: 25244186 - N Engl J Med. 2014 Oct 16;371(16):1481-95 – reference: 23209706 - PLoS One. 2012;7(11):e50316 – reference: 19369328 - J Virol. 2009 Jul;83(13):6917-21 – reference: 6310859 - Virology. 1983 Jul 30;128(2):310-8 – reference: 19369954 - Nat Rev Microbiol. 2009 May;7(5):393-400 – reference: 21987747 - J Infect Dis. 2011 Nov;204 Suppl 3:S757-60 – reference: 13456358 - Virology. 1957 Aug;4(1):41-52 – reference: 20920247 - Virol J. 2010;7:257 – reference: 9988191 - J Infect Dis. 1999 Feb;179 Suppl 1:S248-58 – reference: 21349180 - Virol J. 2011;8:81 – reference: 24046765 - Front Microbiol. 2013 Sep 05;4:267 – reference: 21047966 - J Virol. 2011 Jan;85(2):1025-35 – reference: 19023410 - PLoS Pathog. 2008 Nov;4(11):e1000212 – reference: 20439981 - Am J Trop Med Hyg. 2010 May;82(5):954-60 – reference: 7041255 - Science. 1982 Mar 26;215(4540):1577-85 – reference: 24011860 - Trends Microbiol. 2013 Nov;21(11):583-93 – reference: 14633608 - Am J Pathol. 2003 Dec;163(6):2347-70 – reference: 22247782 - PLoS One. 2012;7(1):e29608 – reference: 17921984 - Nat Biotechnol. 2007 Oct;25(10):1084-7 – reference: 24738640 - N Engl J Med. 2014 Oct 9;371(15):1418-25 – reference: 16588529 - Proc Natl Acad Sci U S A. 1942 Apr;28(4):127-130.1 – reference: 21987755 - J Infect Dis. 2011 Nov;204 Suppl 3:S804-9 – reference: 8666162 - FASEB J. 1996 Jun;10(8):859-64 – reference: 20049699 - EMBO Mol Med. 2009 Apr;1(1):10-8 – reference: 23223188 - Viruses. 2012 Dec;4(12):3511-30 – reference: 8969248 - Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 – reference: 7817880 - Adv Virus Res. 1994;44:69-160 – reference: 11602743 - J Virol. 2001 Nov;75(22):11025-33 – reference: 20448082 - Toxicol Pathol. 2010 Jun;38(4):642-57 – reference: 10489346 - Virology. 1999 Sep 15;262(1):114-28
SSID	ssj0014464
Score	2.3982687
Snippet	This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	6773
SubjectTerms	Animals Disease Models, Animal Ebolavirus - growth & development Ebolavirus - pathogenicity Ebolavirus - physiology Haplorhini Hemorrhagic Fever, Ebola - mortality Hemorrhagic Fever, Ebola - pathology Hemorrhagic Fever, Ebola - virology Macaca fascicularis Serial Passage Survival Analysis Viral Load Viral Plaque Assay Virulence
Title	Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques
URI	https://www.ncbi.nlm.nih.gov/pubmed/25903348 https://www.proquest.com/docview/1701344924
Volume	89
WOSCitedRecordID	wos000355593000021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qFbz4ftQXEbyG7maz3c1JRCwqWvZgS29Lkk2kYDe12xb6753sg54EwcueEgiTyez3Zb7MIHQHmNhXXHvEUMEJiyJOhM8VkQawvgxDU73iH75F_X48GvGkvnAralllExPLQJ1Z5e7IO65ueMAY0IX76TdxXaNcdrVuobGJWgFAGSfpikbrLAJQnTKr7GpmOmTQCN9p3HkdvjhJF-PED38Hl-VPprf_3-UdoL0aXuKHyh8O0YbOj9BO1XBydYxkUnsKmVuS9Aa43H9sDX6SwHHxcjxbFHjcNC4pcJ2_wco6sQcWeYaLBUQX8E8YhtUqtxP79QmTJkIJt-ATNOg9fTw-k7rLAlEsDuYk07EWnvBNl4dR5imfSQ6IW-qYcuEFTHZl3PW1FJRyzUxIuYGBkYwUIBPFDT1FW7nN9TnCRjBX-YFrqgTYQstMSQ6cJVSuRo4ybXTbGC8FL3apCZFruyjStfna6KzagXRaldtIgaB57r3wxR9mX6JdQDRhpae9Qi0DZ1hfo221nI-L2U3pHvDtJ-8_07XFcA
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Particle-to-PFU+ratio+of+Ebola+virus+influences+disease+course+and+survival+in+cynomolgus+macaques&rft.jtitle=Journal+of+virology&rft.au=Alfson%2C+Kendra+J&rft.au=Avena%2C+Laura+E&rft.au=Beadles%2C+Michael+W&rft.au=Staples%2C+Hilary&rft.date=2015-07-01&rft.eissn=1098-5514&rft.volume=89&rft.issue=13&rft.spage=6773&rft_id=info:doi/10.1128%2Fjvi.00649-15&rft_id=info%3Apmid%2F25903348&rft_id=info%3Apmid%2F25903348&rft.externalDocID=25903348
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon